Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites  

作　　者：Jing Lu Xiao-Feng Li Li-Xia Kong Lin Ma Su-Huan Liao Chang-You Jiang 

机构地区：[1]Department of Gastroenterology,the Fifth Affiliated Hospital of Sun Yat-Sen University [2]Department of Oncology,the Fifth Affiliated Hospital of Sun Yat-Sen University [3]Health Bureau of Jinwan District

出　　处：《World Journal of Gastroenterology》2013年第40期6883-6887,共5页世界胃肠病学杂志（英文版）

基　　金：Supported by Fund of Science and Technology Plan Project in Zhuhai,No.PC20061084

摘　　要：AIM:To investigate the mRNA expression of cyclooxygensae-2(COX-2)in benign and malignant ascites,and to explore the difference in COX-2 mRNA expression among different diseases.METHODS:A total of 36 samples were collected from the Fifth Affiliated Hospital of Sun Yat-Sen University and divided into two experimental groups:benign ascites(n=21)and malignant ascites(n=15).Benign ascites included cirrhotic ascites(n=10)and tuberculous ascites(n=5).Malignant ascites included oophoroma(n=7),cancer of colon(n=5),cancer of the liver(n=6),gastric cancer(n=2),and bladder carcinoma(n=1).The mRNA expression of COX-2 in ascites was examined with reverse transcriptase polymerase chain reaction(RT-PCR)technology,and the positive rate of COX-2 mRNA was compared between different diseases.RESULTS:The positive rate of COX-2 mRNA in malignant ascites was 42.9%(9/21),which was significantly higher than in benign ascites,6.7%(1/15),difference being significant between these two groups(χ2=4.051,P=0.044).The proportion of the positive rate in the malignant ascites was as follows:ovarian cancers57.1%(4/7),colon cancer 40.0%(2/5),liver cancer33.3%(2/6),gastric cancer 50.0%(1/2),and bladder cancer 0.00%(0/1).However,there was no significant difference in COX-2 mRNA expression among various tumors with malignant ascites(χ2=1.614,P=0.806).Among the benign ascites,COX-2 mRNA levels were different between the tuberculous ascites(0/5)and cirrhotic ascites(1/10),but there was no significant difference(P=1.000).CONCLUSION:COX-2 mRNA,detected by RT-PCR,is useful in the differential diagnosis of benign and malignant ascites,which also has potential value in the clinical diagnosis of tumors.AIM: To investigate the mRNA expression of cyclooxygensae-2 (COX-2) in benign and malignant ascites, and to explore the difference in COX-2 mRNA expression among different diseases. METHODS: A total of 36 samples were collected from the Fifth Affiliated Hospital of Sun Yat-Sen University and divided into two experimental groups: benign ascites (n = 21) and malignant ascites (n = 15). Benign ascites included cirrhotic ascites (n = 10) and tuberculous ascites (n = 5). Malignant ascites included oophoroma (n = 7), cancer of colon (n = 5), cancer of the liver (n = 6), gastric cancer (n = 2), and bladder carcinoma (n = 1). The mRNA expression of COX-2 in ascites was examined with reverse transcriptase polymerase chain reaction (RT-PCR) technology, and the positive rate of COX-2 mRNA was compared between different diseases. RESULTS: The positive rate of COX-2 mRNA in malignant ascites was 42.9% (9/21), which was significantly higher than in benign ascites, 6.7% (1/15), difference being significant between these two groups (χ2 = 4.051, P = 0.044). The proportion of the positive rate in the malignant ascites was as follows: ovarian cancers 57.1% (4/7), colon cancer 40.0% (2/5), liver cancer 33.3% (2/6), gastric cancer 50.0% (1/2), and bladder cancer 0.00% (0/1). However, there was no significant difference in COX-2 mRNA expression among various tumors with malignant ascites (χ2 = 1.614, P = 0.806). Among the benign ascites, COX-2 mRNA levels were different between the tuberculous ascites (0/5) and cirrhotic ascites (1/10), but there was no significant difference (P = 1.000). CONCLUSION: COX-2 mRNA, detected by RT-PCR, is useful in the differential diagnosis of benign and malignant ascites, which also has potential value in the clinical diagnosis of tumors.

关 键 词：ASCITES Cyclooxygensae-2 MRNA Reverse transcriptase POLYMERASE chain reaction MALIGNANT tumor 

分 类 号：R575.2[医药卫生—消化系统]